血清CEA水平与肺癌分期、近期疗效及生存时间的相关性研究

目的：研究肺癌患者血清CEA水平与肺癌分期、近期疗效及生存时间的关系。方法：确诊为肺癌的92例患者，化疗前、后常规检查血清CEA，评估其变化，所有人组患者随访5年。结果：92例肺癌患者中，CEA升高者为36．95％（34／92），SCLC为13．33％（2／15），NSCLC为41．55％（32／77），其中腺癌43．1％（25／58）、鳞癌37．5％（6／16）、腺鳞癌33．3％（1／3）。SCLC血清CEA增高为Ⅱ度-Ⅲ度。NSCLC血清CEA增高多为Ⅲ度-Ⅳ度。NSCLC中血清CEA增高为Ⅲb期、Ⅳ期患者。化疗后SCLC患者血清CEA1例降至正常，1例升高。NSCLC患者血清CEA正常或降低者为22例（68．75％）。CEA增高的NSCLC患者中位生存时间及总的生存时间为9．5月和19月。CEA增高的SCLC患者中位生存时间及总的生存时间为9．1月及18．2月。结论：血清CEA水平与肺癌分期、疗效及生存时间有关。晚期肿瘤CEA增高，化疗后CEA明显下降，CEA增高的患者预后差、生存时间短。

Correlation between serum CEA level and stage, response, survival in patients with lung cancer

Objective：To syudy the relation between serum CEA levels and stage, response survival in patients with lung cancer. Methods ： Total of 92 lung cancer patients were examined for serum CEA levels before and after chemotherapy, and were followed up for 5 years. Results：Higher serum CEA levels were 36.95% （34/92）, 13.33% （2/15） in SCLC ; 41.55% （ 32/77 ） in NSCLC ; 32.46% （25/77） in adenocareinoma; 7.79% （ 6/77 ） in squamous cell carcinoma;the overall survival was 19 months in NSCLC ; 18.2 months in SCLC. Condusion：Higher serum CEA levels were related to stage ,response and survival in patients with lung eancer, they were found in advaneed stage and reduced after chemotherapy. The prognosis was poor and survival was shorter in patients with high serum tumor markers.